Testing the Combination of Two Anti-cancer Drugs, Peposertib (M3814) and Tuvusertib (M1774) for Advanced Solid Tumors
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Gregory M Cote
Dana-Farber - Harvard Cancer Center LAO
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
6 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- National Cancer Institute Developmental Therapeutics Clinic
Bethesda, Maryland, United States
A P. ChenRecruiting - National Institutes of Health Clinical Center
Bethesda, Maryland, United States
Active, not recruiting - Dana-Farber Cancer Institute
Boston, Massachusetts, United States
Candace L. HaddoxRecruiting - Massachusetts General Hospital Cancer Center
Boston, Massachusetts, United States
Gregory M. CoteRecruiting - Nyu Langone Hospital - Long Island
Mineola, New York, United States
Nancy ChanRecruiting - Laura and Isaac Perlmutter Cancer Center at Nyu Langone
New York, New York, United States
Nancy ChanRecruiting
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 7 Jun 2024
- Primary completion
- 31 Aug 2026
- Completion
- 31 Aug 2026
- Last update posted
- 17 Jun 2026
- Registered enrollment
- 66
- Registry id
- NCT05687136
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.